These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 26889975)

  • 21. Randomized phase II study evaluating a carbon ion boost applied after combined radiochemotherapy with temozolomide versus a proton boost after radiochemotherapy with temozolomide in patients with primary glioblastoma: the CLEOPATRA trial.
    Combs SE; Kieser M; Rieken S; Habermehl D; Jäkel O; Haberer T; Nikoghosyan A; Haselmann R; Unterberg A; Wick W; Debus J
    BMC Cancer; 2010 Sep; 10():478. PubMed ID: 20819220
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The clinical value of patient-derived glioblastoma tumorspheres in predicting treatment response.
    D'Alessandris QG; Biffoni M; Martini M; Runci D; Buccarelli M; Cenci T; Signore M; Stancato L; Olivi A; De Maria R; Larocca LM; Ricci-Vitiani L; Pallini R
    Neuro Oncol; 2017 Aug; 19(8):1097-1108. PubMed ID: 28204560
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rational incorporation of selenium into temozolomide elicits superior antitumor activity associated with both apoptotic and autophagic cell death.
    Cheng Y; Sk UH; Zhang Y; Ren X; Zhang L; Huber-Keener KJ; Sun YW; Liao J; Amin S; Sharma AK; Yang JM
    PLoS One; 2012; 7(4):e35104. PubMed ID: 22496897
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Health-related quality of life, cognitive screening, and functional status in a randomized phase III trial (EF-14) of tumor treating fields with temozolomide compared to temozolomide alone in newly diagnosed glioblastoma.
    Zhu JJ; Demireva P; Kanner AA; Pannullo S; Mehdorn M; Avgeropoulos N; Salmaggi A; Silvani A; Goldlust S; David C; Benouaich-Amiel A;
    J Neurooncol; 2017 Dec; 135(3):545-552. PubMed ID: 28849310
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of field strength on glioblastoma multiforme response in patients treated with the NovoTTF™-100A system.
    Turner SG; Gergel T; Wu H; Lacroix M; Toms SA
    World J Surg Oncol; 2014 May; 12():162. PubMed ID: 24884522
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Toxicity and outcome of radiotherapy with concomitant and adjuvant temozolomide in elderly patients with glioblastoma: a retrospective study.
    Saito K; Mukasa A; Narita Y; Tabei Y; Shinoura N; Shibui S; Saito N
    Neurol Med Chir (Tokyo); 2014; 54(4):272-9. PubMed ID: 24257502
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Time trends in glioblastoma multiforme survival: the role of temozolomide.
    Dubrow R; Darefsky AS; Jacobs DI; Park LS; Rose MG; Laurans MS; King JT
    Neuro Oncol; 2013 Dec; 15(12):1750-61. PubMed ID: 24046259
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting autophagy to sensitive glioma to temozolomide treatment.
    Yan Y; Xu Z; Dai S; Qian L; Sun L; Gong Z
    J Exp Clin Cancer Res; 2016 Feb; 35():23. PubMed ID: 26830677
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase I trial of hypofractionated intensity-modulated radiotherapy with temozolomide chemotherapy for patients with newly diagnosed glioblastoma multiforme.
    Chen C; Damek D; Gaspar LE; Waziri A; Lillehei K; Kleinschmidt-DeMasters BK; Robischon M; Stuhr K; Rusthoven KE; Kavanagh BD
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):1066-74. PubMed ID: 20932651
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Standard (60 Gy) or short-course (40 Gy) irradiation plus concomitant and adjuvant temozolomide for elderly patients with glioblastoma: a propensity-matched analysis.
    Minniti G; Scaringi C; Lanzetta G; Terrenato I; Esposito V; Arcella A; Pace A; Giangaspero F; Bozzao A; Enrici RM
    Int J Radiat Oncol Biol Phys; 2015 Jan; 91(1):109-15. PubMed ID: 25442339
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Phase 2 Trial of Neoadjuvant Temozolomide Followed by Hypofractionated Accelerated Radiation Therapy With Concurrent and Adjuvant Temozolomide for Patients With Glioblastoma.
    Shenouda G; Souhami L; Petrecca K; Owen S; Panet-Raymond V; Guiot MC; Corredor AG; Abdulkarim B
    Int J Radiat Oncol Biol Phys; 2017 Mar; 97(3):487-494. PubMed ID: 28011051
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Glioblastoma stem cells resistant to temozolomide-induced autophagy.
    Fu J; Liu ZG; Liu XM; Chen FR; Shi HL; Pangjesse CS; Ng HK; Chen ZP
    Chin Med J (Engl); 2009 Jun; 122(11):1255-9. PubMed ID: 19567133
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Can we afford to add chemotherapy to radiotherapy for glioblastoma multiforme? Cost-identification analysis of concomitant and adjuvant treatment with temozolomide until patient death.
    Wasserfallen JB; Ostermann S; Pica A; Mirimanoff RO; Leyvraz S; Villemure JG; Stupp R
    Cancer; 2004 Nov; 101(9):2098-105. PubMed ID: 15389472
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Radiotherapy for glioblastomas: from radiobiology to concomitant chemotherapy].
    Simon JM; Toubiana T; Lang P; Taillibert S; Mazeron JJ
    Cancer Radiother; 2005 Sep; 9(5):322-31. PubMed ID: 16095943
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Postoperative neoadjuvant temozolomide before radiotherapy versus standard radiotherapy in patients 60 years or younger with anaplastic astrocytoma or glioblastoma: a randomized trial.
    Malmström A; Poulsen HS; Grønberg BH; Stragliotto G; Hansen S; Asklund T; Holmlund B; Łysiak M; Dowsett J; Kristensen BW; Söderkvist P; Rosell J; Henriksson R;
    Acta Oncol; 2017 Dec; 56(12):1776-1785. PubMed ID: 28675067
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neoadjuvant cisplatin plus temozolomide versus standard treatment in patients with unresectable glioblastoma or anaplastic astrocytoma: a differential effect of MGMT methylation.
    Capdevila L; Cros S; Ramirez JL; Sanz C; Carrato C; Romeo M; Etxaniz O; Hostalot C; Massuet A; Cuadra JL; Villà S; Balañà C
    J Neurooncol; 2014 Mar; 117(1):77-84. PubMed ID: 24395350
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A pilot study of hypofractionated radiation therapy with temozolomide for adults with glioblastoma multiforme.
    Terasaki M; Eto T; Nakashima S; Okada Y; Ogo E; Sugita Y; Tokutomi T; Shigemori M
    J Neurooncol; 2011 Apr; 102(2):247-53. PubMed ID: 20640480
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Temozolomide in radio-chemotherapy combined treatment for newly-diagnosed glioblastoma multiforme: phase II clinical trial.
    Lanzetta G; Campanella C; Rozzi A; Nappa M; Costa A; Fedele F; Innocenzi G; Gagliardi FM; Salvati M; Minniti G; Frati A; Frati L; Vecchione A
    Anticancer Res; 2003; 23(6D):5159-64. PubMed ID: 14981983
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutic efficacy of a herpes simplex virus with radiation or temozolomide for intracranial glioblastoma after convection-enhanced delivery.
    Hadjipanayis CG; Fellows-Mayle W; Deluca NA
    Mol Ther; 2008 Nov; 16(11):1783-8. PubMed ID: 18728637
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combined modality treatment of glioblastoma multiforme: the role of temozolomide.
    Nieder C; Adam M; Grosu AL
    Rev Recent Clin Trials; 2006 Jan; 1(1):43-51. PubMed ID: 18393779
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.